Articles tagged "Immunosuppression"

2019 American Transplant Congress
Efficacy of Photobiomodulatory Therapy Combined with Short-Term Immunosuppressants Prolonged Allograft Survival in a Rodent Hind-Limb Model
Y. KUO¹, Y. Li¹, C. Chen¹, R. Chen1¹, G. Brandacher²
¹Division of Plastic Surgery, Department of Surgery,, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ²Department of Plastic Surgery, VCA center, Johns Hopkins University, Baltimore, MD
*Purpose: Photobiomodulation has been applied for accelerating the skeletal muscle repair process. Our formal study demonstrated vitamin D could be involved in allograft survival and…
2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
R. Wolff¹, A. Nasstrom¹, C. Borscheid¹, C. Martin¹, A. Temelie¹, R. Spong², D. Keys², T. B. Dunn³
¹School of Pharmacy, MHealth U of MN Medical Center-Fairview, Mpls, MN, ²Medicine, MHealth U of MN Medical Center-Fairview, Mpls, MN, ³Surgery, U of Pennsylvania, Phila, PA
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…
2019 American Transplant Congress
A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients
T. A. Horwedel¹, C. E. Carthon¹, S. E. January¹, A. Gharabagi¹, R. Delos Santos², J. C. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ²Nephrology, Washington University School of Medicine, Saint Louis, MO
*Purpose: Beginning in December 2015, our center instituted a protocol change moving to de novo use of LCPT. The objective of this study is to…
2019 American Transplant Congress
Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients
R. F. Parsons¹, S. Bumb², H. Decker¹, A. Zahid¹, C. Sullivan¹, T. Pearson¹, C. Larsen¹, M. Levine³, M. Kamoun³, R. A. Bray¹, H. M. Gebel¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Cincinnati, Cincinnati, OH, ³University of Pennsylvania, Philadelphia, PA
*Purpose: Recent evidence suggests that belatacept reduces the durability of pre-existing antibodies to class I and class II human leukocyte antigens (HLA). Belatacept has a…
2019 American Transplant Congress
A Novel Apparatus Mimicking Hypertensive Kidney With Primary Cultured Human Kidney Cells Using Rotational Force: Application To In Vitro Drug Screening In Kidney Transplant Recipients
Y. Kim¹, S. Lee², J. Moon¹, J. Kim¹, M. Yu³, C. Lee⁴, Y. Kim¹, S. Yang⁵, J. Jeong¹, J. Seon¹
¹Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ²Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, ³Internal Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of, ⁴Internal Medicine, Cheju Halla General Hospital, Cheju, Korea, Republic of, ⁵Kidney Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Cell culture is an essential part of the development for various medical technologies such as identifying the cause of the disease and developing new…
2019 American Transplant Congress
Incidence, Risk Factors, Outcomes and Clinical Management of BK Viremia in the Modern Era of Kidney Transplantation
J. Kim
Toronto General Hospital, Toronto, ON, Canada
*Purpose: BK viremia is endemic among kidney transplant recipients (KTR). Previous work has not compared the incidence, risk factors, and outcomes of any vs. clinically…
2019 American Transplant Congress
Immunologic Outcomes In Recipients Of Orthotopic Liver Transplant Induced Only With Steroids
S. N. Merwat, A. T. Chatila, M. Bilal, R. Kulkarni, H. L. Stevenson, J. H. Fair, S. K. Merwat, T. Kozlowski, M. A. Mujtaba
The University of Texas Medical Branch, Galveston, TX
*Purpose: Liver allografts are resistant to antibody mediated rejection (AMR) in the presence of preformed alloantibodies. In most cases donor specific antibodies (DSAs) disappear a…
2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
J. D. Motter¹, K. Jackson¹, S. Bae¹, X. Luo¹, J. Long¹, L. Kucirka¹, B. Orandi², A. Muzaale¹, J. Coresh¹, J. Garonzik-Wang¹, D. Segev¹, A. Massie¹
¹Johns Hopkins University, Baltimore, MD, ²University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…
2019 American Transplant Congress
Early Use of Everolimus Plus Reduced Tacrolimus vs Standard Tacrolimus in De Novo Livertransplant Recipients: 12 Months Efficacy and Safety Data from HEPHAISTOS Study
B. Nashan¹, P. Schemmer¹, H. Schlitt¹, A. Pascher¹, C. Klein¹, U. Neumann¹, I. Kroeger², P. Wimmer², F. Braun¹
¹Study Group, Hephaistos, Germany, ²Novartis Pharma GmbH, Nuernberg, Germany
*Purpose: The HEPHAISTOS study was set up to compare early use of everolimus [EVR] combined with reduced tacrolimus [rTAC] versus standard-dose tacrolimus [TAC-C) in de…
2019 American Transplant Congress
Kidney Xenotransplantation from Genetically Engineered Pigs to Baboons with FDA-Approved Immunosuppressive Therapy
T. Yamamoto¹, H. Hara¹, J. Foote¹, E. C. Klein², H. J. Schuurman³, L. Wang¹, Q. Li¹, H. Zhou¹, J. Li¹, J. A. Tector¹, Z. Zhang², M. Ezzelarab², R. Lovingood¹, D. Ayares⁴, D. E. Eckhoff¹, D. K. Cooper¹, H. Iwase¹
¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pittsburgh, Pittsburgh, PA, ³Schubiomed Consultancy, Utrecht, Netherlands, ⁴Revivicor, Blacksburg, VA
*Purpose: Genetically-engineered pigs might present a solution to the critical shortage of organs for clinical transplantation. The aims of this study were to evaluate the…